A research team led by Beate Averhoff and Volker Müller of Goethe University Frankfurt has discovered a fundamental mechanism that helps the dreaded hospital pathogen Acinetobacter baumannii to survive.
AstraZeneca snaps up Amolyt for $1.05bn to boost rare disease pipeline – Pharmaceutical Technology
Share this article AstraZeneca’s rare disease portfolio generated $7.76bn in global sales in 2023, as per the company’s Q4 financials. Image Credit: EllaSt / Shutterstock.